NCT05564390 2026-03-18
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
11 trialsNCT06672146 2026-03-17
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03728335 2026-03-13
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT03683433 2026-03-05
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03383575 2026-02-17
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06756308 2025-12-23
A Study of Enasidenib in People With T-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06176989 2025-10-20
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05401097 2025-05-14
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT04281498 2025-02-04
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT04522895 2024-09-19
IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT
Heinrich-Heine University, Duesseldorf
Phase 2 Completed
NCT03881735 2021-03-10
Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Roswell Park Cancer Institute
Phase 2 Withdrawn